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Experimental analysis of the effects of individual components of
complex mammalian systems is frequently impeded by compen-
satory adjustments that animals make to achieve homeostasis. We
here introduce a genetic procedure for eliminating this type of
impediment, by using as an example the development and testing
of a transgene for ‘‘genetically clamping’’ the expression of renin,
the major homeostatically responding component of the renin–
angiotensin system, one of the most important regulators of blood
pressure. To obtain a renin transgene whose expression is genet-
ically clamped at a constant level, we have used single-copy
chosen-site gene targeting to insert into a liver-specific locus a
single copy of a modified mouse renin transgene driven by a
liver-specific promoterenhancer. The resulting transgene ex-
presses renin ectopically at a constant high level in the liver and
leads to elevated plasma levels of prorenin and active renin. The
transgenic mice display high blood pressure, enhanced thirst, high
urine output, proteinuria, and kidney damage. Treatment with the
angiotensin II type I receptor antagonist, losartan, reduces the
hypertension, albuminuria, and kidney damage, but does not
affect expression of the transgene. This genetically clamped renin
transgene can be used in models in which hypertension and its
complications need to be investigated in a high proreninrenin
environment that is not subject to homeostatic compensations by
the animal when other factors are changed.
Complex organisms maintain their internal environment con-stant by a variety of homeostatic adjustments that return the
internal milieu to near normality when it is disturbed. These
homeostatic adjustments help to maintain the normal status of
an organism but present serious challenges to investigators
wishing to dissect the individual components within complex
systems. To overcome these obstacles, physiologists have for
many years used sophisticated sensors and infusion pumps to
‘‘clamp’’ the level of metabolites or other variables that are
normally subject to homeostasis (1). A prime example is the
euglycemic clamp, the gold standard for research requiring
measurements of insulin resistance in vivo (2).
Two alterations are required to achieve a comparable goal by
genetic means. One alteration is to inactivate the endogenous
gene that normally responds to homeostatic cues. The other
alteration is to provide a new source of the protein of interest by
introducing a transgene whose expression is of the desired
strength but is not sensitive to homeostasis. ‘‘Genetic clamping’’
is obtained when the two alterations are combined by breeding.
The complex system we have chosen for developing our proce-
dure is the renin–angiotensin system (RAS), one of the most potent
regulators of blood pressure (BP). Renin is the major homeostatic
responder of the RAS, and it is its gene that we propose to clamp.
Inactivation of the endogenous renin gene has already been
achieved by gene targeting (ref. 3 and our own unpublished
experiments). The design and testing of the genetically clamped
renin transgene is the subject of our present investigation.
There are several technical limitations to generating mice with
active renin expression by conventional transgenic approaches.
Many of these issues are discussed in detail in a recent review by
Cvetkovic and Sigmund (4), but we summarize a few key points
here. Active renin is the proteolytic product of prorenin after a
cleavage reaction that is restricted to the juxtaglomerular cells of the
kidney (5). Species differences affect renin specificity, as illustrated
by the finding that human renin does not react with rodent
angiotensinogen or vice versa (6). Transgenic mouse lines have
been made with varying lengths of the human renin gene locus; they
express human prorenin, which itself may have distinct and signif-
icant biological activity (7, 8), and human renin. Although the
transgenic human renin does not cleave mouse angiotensinogen,
these mice have been valuable for studies of human renin gene
regulation and RAS physiology when they are crossed to transgenic
mice that express human angiotensinogen (9, 10). However, the
crossing of different transgenic lines inevitably results in complex
genetic backgrounds. An additional complication is that, unlike rats
and humans, wild mice and some (but not all) laboratory strains
have two tandemly arranged biologically active renin genes, Ren1d
and Ren2 (11, 12).
To circumvent some of the technical problems discussed above,
we have developed a conceptually and genetically simple renin
transgene that is expressed under the control of a liver-specific
promoter and is targeted into the genome as a single copy in a locus
that is active in the liver, an organ that is uninvolved in the
regulation of blood pressure. In this way, the ectopic expression of
the transgene is clamped and independent of the complex homeo-
static compensations that occur with the natural renin gene in the
kidney. An additional advantage of this targeted transgene is that
it eliminates the uncertain copy number and variable position
effects inherent in conventional transgenic approaches. This mo-
nogenic model of proreninactive renin overexpression is proving
of value in several contexts in addition to its future use for
genetically clamping renin expression in the whole animal.
Materials and Methods
The targeting construct (Fig. 1) consisted of (i) a liver-specific
albumin promoterenhancer (13), (ii) a synthetic mouse renin
cDNA that includes at its 3 end a c-myc epitope tag, (iii) a rabbit
-globin 3 untranslated region (UTR), (iv) 5 and 3 homolo-
gous regions for gene targeting at an apolipoprotein locus, and
(v) neomycin resistance and thymidine kinase cassettes. The
synthetic renin cDNA was constructed by using parts of the
Ren-2 and Ren-1d genes assembled in a manner that enables
expression of the synthetic renin to be discriminated from that
of either endogenous renin gene by quantitative reverse tran-
scription (RT)-PCR. The synthetic gene includes an N glyco-
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sylation site for increased stability, and was engineered so that
processing from prorenin to renin can be efficiently achieved in
hepatic or other cells by the ubiquitous enzyme furin (14). The
sequence of the synthetic renin cDNA is provided as supporting
information, which is published on the PNAS web site, www.
pnas.org.
The transgene was targeted to the apolipoprotein locus be-
tween the Apoa1 and Apoc3 genes by using homologous recom-
bination in 129-derived SvEv embryonic stem (ES) cells (TC-1,
a gift from Dr. Phil Leder, Harvard University, Boston), as
described (15). Two separate mouse lines were established that
differed only in the presence or absence of a 20-bp oligonucle-
otide insert (16) in the 5 UTR of the transgene. The overall
physiological parameters of these two mouse lines were substan-
tially identical and so vastly different from wild type (Wt)
controls that the data from the two were combined.
For PCR-based genotyping (Fig. 1), we used three primers;
primer 1: 5- TGGGATTCTAACCCTGAGGACC-3; primer 2:
5-CACAGATTGTAACTGCAAATCTGTCG-3; primer 3: 5-
GTTCTTCTGAGGGGATCGGC-3.
Quantitative RT-PCR for renin was performed on the ABI
7700 Sequence Detection System using primers and a TaqMan
probe as described (17).
For general histology, 5-m-thick paraffin sections were
stained with hematoxylin and eosin (H&E) and Masson’s-
Trichrome reagents. Immunohistochemistry for renin was per-
formed as described (18). The total number of glomeruli (TG)
and those with renin-positive juxtaglomerular apparatus (JGA)
were counted in two sections per kidney. The percentage of
renin-positive JGA was determined as (number of renin-positive
JGA in all sections)  100TG (18).
Mice were placed in metabolic cages for 3 days with free access
to food and water. For water-deprivation studies, water was
denied for 20 h. Urine osmolality was determined by freezing
point depression. Plasma and urine electrolytes, creatinine,
glucose, urea, and protein were assayed in the University of
North Carolina Pathology Core Animal Chemistry Facility.
Blood pressure was measured by tail cuff as described (19).
Losartan (Merck) (0.12g/liter; 15 mg per kg per day) was
administered in the drinking water.
RIA for angiotensin I (Ang I) was performed as described
(20) by using a commercially available kit from NEN Life
Science Products. Albumin excretion rate [g per 30 g body
weight (BW) per day] was calculated from the urine albumin
determined by ELISA using conventional methods.
All experiments were conducted with 3- to 6-month-old, F1
males, and were approved by the Institutional Animal Care and
Use Committee of the University of North Carolina, Chapel Hill.
Statistical analyses were performed with JPM software (SAS,
Cary, NC). Values are presented as mean  SE. Significance was
assessed by ANOVA.
Results
To generate mice that have elevated levels of circulating mouse
renin not subject to homeostatic influences we used the single-
copy chosen-site integration gene targeting procedure (15, 21) to
insert a synthetic renin cDNA driven by a liver-specific promoter
and enhancer into the liver-specific apolipoprotein Apoa1
Apoc3 locus. We chose this locus because of its liver-specific
properties (15) and because targeting genes to this region can be
achieved with high efficiency (22). Heterozygous or homozygous
disruption of this locus results in viable, fertile, and otherwise
normal animals so that the transgene can be obtained as either
one (heterozygotes) or two (homozygotes) copies. As shown in
Fig. 1 A–C, a cDNA fragment coding for a synthetic mouse
prorenin gene, consisting of parts of the Ren-2 and Ren-1d mouse
genes and designated Ren21d, was modified to include an
N-glycosylation site and a furin cleavage site. These modifica-
tions enable the cleavage and secretion of the prorenin transgene
product by the liver. To ensure that the expression of the renin
transgene is free from homeostatic regulation, the Ren21d
cDNA was placed under the control of the liver-specific albumin
promoterenhancer (13). Its 3 UTR was from a rabbit -globin
gene. Correctly targeted ES cells were first identified by PCR
(Fig. 1D) and then confirmed by Southern blot analysis (Fig. 1E)
as depicted. Male chimeric mice were mated to C57BL6 females
to generate the F1 male mice used in our present studies. They
have one copy of the renin transgene (RenTg), are Wt at the
natural renin gene locus and, because they are F1s, they are
otherwise genetically identical.
The albumin promoterenhancer has been well characterized
and used to direct transgene expression exclusively in the liver
(23–27). Multiple-tissue Northern analysis confirmed that expres-
sion of our RenTg occurs in the liver but not in other representative
tissues, including heart, brain, kidney, small intestine, and subman-
dibular gland (data not shown). Quantitative RT-PCR determined
that high levels of renin mRNA were present in the livers of RenTg
mice (Fig. 2A). Endogenous renin mRNA levels in the kidneys of
the RenTg mice were very suppressed compared with the Wt
controls (Fig. 2A), and immunohistochemistry for renin in the
kidney showed that only 5%  4% of the glomeruli stained for
renin in the RenTg mice, compared with 65%  7% in Wt animals
(P  0.0001; Figs. 2 B–D). To test our expectation that the RenTg
expression was free from homeostatic regulation, mice were treated
for 4 weeks with the angiotensin II receptor 1a (AT1) antagonist,
Fig. 1. Generation of RenTg mice. (A) Endogenous apolipoprotein Apoa1
Apoc3 locus. (B) Targeting vector. (C) Targeted allele after homologous re-
combination. (D) PCR-based strategy for selection of targeted ES cells and for
routine genotyping of RenTg animals. Primers 1 and 2 (A) amplify a 430-bp
band from the endogenous allele, whereas primers 1 and 3 (C) amplify a
330-bp band from the targeted allele. (E) Southern blot used to confirm
correctly targeted ES cells. Digestion of genomic DNA with BamHI results in a
9.2-kb fragment for the Wt allele and a 5.1-kb fragment for the targeted allele
when probed with the fragment depicted in A.











losartan and renin mRNA levels were measured with quantitative
RT-PCR. As expected, losartan increased endogenous kidney renin
levels in Wt mice, but it had no effect on renin levels in the RenTg
liver although it modestly increased the levels of endogenous renin
expression in the kidney of the transgenic mice (Fig. 2 A).
The RenTg mice had over six times Wt levels of total renin
plasma concentration (628  26 ng Ang I per ml per h vs. 95 
13 ng Ang I per ml per h, P  0.0001). The ratio of prorenin to
renin in the transgenic mice was similar to Wt (1.8 in RenTg vs
1.1 in Wt controls) establishing that cleavage of the synthetic
prorenin in the liver was comparable in degree to the cleavage
of natural prorenin in the kidney.
We used a computerized tail cuff system to show that the
targeted mice had BPs more than 25 mmHg (1 mmHg  133 Pa)
higher than Wt mice (Fig. 3). To establish that the elevated BP
resulted from an increase in angiotensin II (Ang II) signaling, we
measured the BPs of the RenTg mice after a 2-week adminis-
tration of losartan. As shown in Fig. 3, losartan treatment had
little effect on the BP of the Wt mice (from 110  3 mmHg to
105  3 mmHg; P  0.32), but it significantly reduced the BP of
the RenTg mice (from 137  5 mmHg to 118  2; P  0.01) to
almost normal levels (Wt untreated vs Tg treated; P  0.07). We
conclude that the ectopic overexpression of a synthetic renin
gene in the RenTg mice leads to chronic hypertension caused by
an increase in Ang II acting through the AT1 receptor.
The RAS has a broad variety of physiological effects related
to the maintenance of sodium and water balance. We therefore
evaluated the effect of the increased plasma renin on drinking
behavior and urine production in the RenTg mice. The targeted
mice, compared with their Wt counterparts, consumed signifi-
cantly more water (Wt  2.9  0.5 ml vs RenTg  4.8  0.3 ml;
P  0.02) and produced more urine (Wt  1.1  0.1 ml vs
RenTg  2.5  0.4 ml; P  0.03) of dilute osmolality (P  0.01)
(Fig. 4 A–C). To determine whether the production of dilute
urine in the RenTg mice might be caused by an inherent inability
of the renin-depleted kidneys to concentrate urine, mice were
deprived of water for 20 h, and urine osmolality was measured.
Although the urine osmolality remained significantly lower in
RenTg mice after water deprivation (3,488  178 mOsM in Wt
vs. 2,886  154 mOsM in RenTg, P  0.03), there was a
concomitant increase in urine osmolality for both Wt and RenTg
Fig. 2. Renin Expression in Wt and RenTg mice. (A) Quantitative RT-PCR
shows increased Ren21d expression in liver and decreased endogenous renin
expression in kidney of RenTg mice. Losartan has no effect on the Ren21d
expression in the RenTg mice. Immunostaining for renin in kidney sections
from Wt (B) and RenTg (C) mice. Single arrows indicate positive staining in
glomerular vascular poles. Double arrows identify unstained glomeruli. (Mag-
nification, 260.) (D) Quantitation of positively stained glomeruli. *, P  0.001
vs. Wt, n  6.
Fig. 3. Mean BPs of Wt and RenTg mice with or without losartan treatment
as measured by computerized tail cuff method. *, P  0.0001 vs. other groups;
n  5.
Fig. 4. Metabolic studies on Wt and RenTg mice. (A) Water consumption. (B)
Urine production. (C) Urine osmolality. *, P  0.05 vs. Wt; #, P  0.01 vs. Wt;
n  4.
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mice of approximately 1,000 mOsM (before water deprivation,
Wt  2,737  120 mOsM and RenTg  1,748  206 mOsM)
(Fig. 4C), demonstrating that the kidneys in the transgenic mice
are still capable of concentrating urine.
There were no significant differences in BW, hematocrit,
plasma electrolytes, or urine composition between RenTg and
Wt littermates (Table 1). However, there was a significant
increase in serum creatinine in RenTg mice (21  6 mmol/liter
in RenTg mice vs. 11  4 mmol/liter in Wt; P  0.01), indicating
reduced kidney function.
To further characterize the impact of chronic hypertension on the
decreased kidney function, we measured total protein excretion
rate and proteincreatinine ratio in Wt and RenTg mice. Measure-
ment of total urinary protein revealed that RenTg mice have
proteinuria (706  71 g per 30 g BW per day in RenTg vs 56 
6 g per 30 g BW per day in Wt; P  0.001) (Fig. 5A). Urine
proteincreatinine ratios, which reliably reflect renal function and
overcome urine collection errors (28), are shown in Fig. 5B. This
ratio was significantly elevated in the RenTg mice as compared with
their Wt littermates (0.10  0.006 in RenTg vs 1.3  0.3 in Wt; P 
0.01). SDSPAGE of urine from targeted mice revealed the
presence of an approximately 70-kDa protein, which is similar to the
MW of mouse albumin (29) (Fig. 5C). We confirmed an increase
in albumin excretion in RenTg mice (29  11 g per 30 g BW per
day for RenTg vs 5.1  0.3 g per 30 g BW per day for Wt, P 
0.02) by using an ELISA for mouse albumin (Fig. 5D).
Histology of the kidneys revealed vascular, glomerular and
tubulointerstitial changes indicative of hypertensive nephroscle-
rosis in the RenTg mice when compared with controls (Fig. 6 A,
B, D, and E). The renal cortical sections from targeted mice
showed inflammatory infiltrates, fibrinoid necrosis, and arterial
disruption compatible with severe hypertension (Fig. 6 B and E).
Treatment with losartan lowered the BP (Fig. 3) and improved
the proteinuria in the RenTg mice (Fig. 5 A–C). In addition, a
4-week treatment of losartan substantially ameliorated the ex-
Fig. 6. H&E and Masson’s-Trichrome staining of renal tissue from Wt (A and D), RenTg (B and E), and RenTg treated with losartan for 4 weeks (C and F). gs,
glomerular sclerosis; vs, vascular sclerosis; tf, tubulointerstitial fibrosis; I, inflammatory cell infiltrate. (Magnification, 130.)
Table 1. Body weight, hematocrit, serum, and urine electrolytes
in 4-month-old male RenTg and Wt mice
Wt (n  5) RenTg (n  6) P value
Body weight, g 28.0  1.9 30.4  1.9 0.15
Hematocrit, % 48.9  2.2 51.5  2.5 0.08
Serum
Glucose, mmolliter 5.5  1.2 4.9  0.8 0.32
Sodium, mmolliter 169  3 172  2.0 0.10
Potassium, mmolliter 5.5  0.6 5.6  0.2 0.42
Creatinine, Cr, mmolliter 11  4 21  6 0.01*
Urea, mmolliter 8.5  1.1 10.1  2.2 0.12
Urine (24 hours)
Sodium, mmol per g per BW 4.6  1.2 6.1  1.4 0.20
Potassium, mmol per g per BW 11.3  3.0 15.6  2.9 0.11
Chloride, mmol per g per BW 9.1  2.5 11.8  2.5 0.22
*Denotes a statistically significant difference between RenTg and Wt mice.
Fig. 5. Analysis of urine protein in Wt and RenTg mice. (A) Protein excretion.
(B) Urine proteincreatinine ratio. (C) SDSPAGE of urine. MW represents
molecular weight markers. (D) Albumin excretion rate. *, P  0.01 vs. Wt; †, P 
0.05 vs. untreated RenTG; #, P  0.02 vs. Wt; n  4.











tent of the pathologic changes in the kidneys of the RenTg mice
(Fig. 6 C and F).
Discussion
Chronic hypertension is an important risk factor for morbidity and
mortality in cardiovascular diseases (30) and for the development
and progression of glomerulosclerosis and hypertensive nephro-
sclerosis (31). Treatment of chronic hypertension and prevention of
its secondary renal complications in humans often involves phar-
macological manipulation of the RAS system. It is therefore not
surprising that numerous animal models have been developed to
better understand the genetics and physiology of the RAS and the
pharmacological agents used to regulate it (4, 7, 32–34). However,
a complication in these animal models is the uncontrolled homeo-
static feedback that occurs subsequent to genetic or experimental
manipulations. Developing a model in which the effector molecule
renin is held at a constant level would be of great value. Because
of the complex nature of the renin genes in the commonly used 129
mouse strain, it has been a challenge to generate mouse models that
overexpress renin in a form that is active in mice or that delete both
renin genes (3, 35, 36).
In this paper, we have used single-copy chosen-site gene
targeting to generate a mouse line that produces genetically
clamped high levels of mouse active renin in the liver. By
choosing to express the RenTg in the liver, driven by a liver-
specific promoterenhancer, the ectopically produced active
renin is completely freed from normal renal homeostatic ad-
justments, and is therefore clamped. Moreover, because the
engineered transgene is of mouse origin, the resulting high
circulating active renin is capable of interacting with the other
components of the mouse RAS, and leads to a severe Ang
II-mediated hypertension and to kidney damage. Treatment with
the AT1 receptor antagonist, losartan, reduces the BP and partly
ameliorates the renal damage, indicating that much of the
damage is caused by Ang II andor the high BP. The absence of
complete protection against renal fibrosis is presumably related
either to the limited duration of the treatment (4 weeks) or to the
presence of irreversible damage at the onset of the treatment (6
months old). We stress, however, that the losartan treatment
does not affect the expression of the clamped renin transgene
even though it corrects much of its consequences.
In a related study, Véniant et al. (37) used a conventional
transgenic approach to overexpress rat prorenin in the liver of rats.
Despite a 400-fold increase in plasma prorenin levels, these trans-
genic rats did not have elevated BP, presumably because the
circulating prorenin secreted from the liver could not be cleaved in
the blood stream into active renin. Nevertheless, their transgenic
model developed severe renal lesions even in the absence of
hypertension. The authors concluded that prorenin itself can act
locally to increase Ang II levels, a hypothesis that has been
supported by other studies demonstrating enzymatic activity of
prorenin in nonrenal tissues (8, 38, 39). Given these findings and
because our RenTg mice also have circulating levels of prorenin, it
is possible, although perhaps not likely (because our prorenin levels
are only 8 times normal) that in addition to the hypertension,
increased circulating prorenin levels are partly involved in the
kidney damage.
In conclusion, our genetically clamped RenTg mouse pro-
duces physiologically active renin at a constant level that is
insensitive to normal homeostatic signals and is expressed in an
organ that is uninvolved in BP regulation. Therefore, the
clamped renin transgene provides an uncomplicated means for
generating animals in which to study the pathology of chronic
hypertension and the pharmacologic action of drugs used to
regulate the RAS. We are currently testing variants of the
current RenTg so that the level of genetically clamped renin can
be matched to different experimental situations.
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